Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBL-054-TCE
- Development stage
- Preclinical
- Lead developer
- LEADS BioLabs
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LBL-054-TCE is a bispecific T-cell engager (TCE) antibody developed by Nanjing Leads Biolabs using its proprietary LeadsBody™ platform. It is designed to simultaneously target Cadherin 17 (CDH17), a tumor-associated antigen highly expressed in gastrointestinal malignancies, and the CD3 epsilon chain on T cells. By cross-linking these two targets, LBL-054-TCE recruits and activates T cells to selectively eliminate CDH17-positive tumor cells. Preclinical studies have demonstrated that the drug exhibits potent binding affinity for CDH17 with no cross-reactivity to other family proteins, and shows CDH17 expression-dependent tumor cell killing with minimal cytokine release. It is currently being investigated for the treatment of various gastrointestinal cancers, including colorectal, gastric, and pancreatic cancers.
- Other names
- LBL-054 (TCE format)
02
Targets
CD3 (T-cell surface glycoprotein CD3)CDH17 (Cadherin-17)
Beyond the preview
Go deeper on LBL-054-TCE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBL-054-TCE.